Duke Health describes menopause care in which estrogen and progesterone can have different roles. That is a useful starting point for someone trying to understand a prescription containing more than one hormone. It is not a catalogue of interchangeable capsules, patches and creams.
This September 29, 2026 review examines Duke’s menopause service and a Durham clinic, alongside the current Prometrium label. Duke does not name an oral progesterone product on the reviewed service pages. The label therefore explains a particular medicine, without establishing that Duke would prescribe or supply it.
In this article
The service is a consultation, not a capsule order
Duke’s menopause service describes evaluation by gynecologists and a range of treatment options. Its Patterson Place practice also explicitly lists menopause care. These are direct clinical services, rather than a hormone information page standing alone. The presence of a service still leaves the consultation’s outcome open: a clinician may need to clarify the concern, medical history and appropriate alternatives before discussing a medicine.
The University of Utah review examines a longer description of that initial discussion. The useful comparison is what each institution explains about the encounter. Neither institution’s name identifies the contents of a future prescription or establishes that progesterone is the answer to every menopause concern.
Separate the two medicine identities
The Duke page explicitly distinguishes estrogen treatment from estrogen combined with progesterone. It then describes several hormone-delivery methods. Reading those statements together requires care: the page does not assign every listed method to every hormone. A patch mentioned in a broad treatment overview cannot establish which progesterone product accompanies it. Duke’s treatment description supports the range of discussions, not a route-by-route formulary.
A useful written explanation would identify each medicine independently, including what it is intended to do. Our guide to oral progesterone’s purpose develops that distinction. A combined care plan is easier to understand when its components retain their own names, instructions and questions instead of becoming one vague “hormone treatment.”
A named label sets a narrower boundary
The Prometrium label describes oral micronized progesterone. Its patient information includes use with estrogen after menopause in a woman with a uterus to reduce the risk of excessive growth of the uterine lining. That product-specific role should not be expanded into proof that any progesterone preparation, in any route, offers equivalent protection.
Duke’s use of the word bioidentical does not settle this distinction. Chemical identity, route and regulatory status answer different questions. FDA notes that compounded drugs do not receive its premarket approval. The reviewed Duke pages do not establish that a particular patient would receive a compounded preparation, and this review does not attribute one to the clinic.
The capsule ingredient question needs an actual product
Prometrium’s documented inactive ingredients include peanut oil, and its label excludes use in people allergic to peanuts. That is a material product detail, not a warning that can simply be attached to every capsule bearing the word progesterone. The exact supplied product and its current information would be needed for an ingredient assessment. The label’s description and contraindications are the relevant evidence here.
The capsule excipients guide explains why the active ingredient alone is an incomplete identifier. A conversation with the prescribing clinician and dispensing pharmacist can address the particular formulation and allergy history. This review cannot resolve that conversation using Duke’s general menopause page.
Connect the treatment discussion to a real practice
Duke Women’s Health Associates at Patterson Place identifies a Durham location and explicitly includes menopause among its services. Its practice page explains patient-portal functions, including communication and refill requests. A request function is a way to contact the team; it does not promise that a prescription will be renewed or that a particular pharmacy carries it.
The Cleveland Clinic review offers a different organizational comparison, because its group menopause visits may lead to a separate individual appointment. Duke’s location evidence should likewise be read at the practice level. General health-system reach is not confirmation of access from another state or a guarantee of the same services everywhere.
Cost belongs to the encounter and the prescription
The Patterson Place page discusses insurance participation and the need to check coverage for the relevant provider and location. It does not supply a complete price for an oral progesterone treatment plan. A consultation, a test and a medicine can generate different charges or coverage decisions. Duke’s practice information cannot turn those separate items into an advertised capsule package.
Before comparing offers, the unresolved costs should therefore remain visible: which clinician and visit are being quoted, whether follow-up is included, and what the actual prescription would cost. A network listing does not answer every benefit question. There is no basis here for a monthly Duke progesterone price, a subscription commitment or guaranteed insurance payment.
Keep the safety discussion attached to the named medicine
Prometrium’s current patient information addresses dizziness and drowsiness and includes serious contraindications and warnings. Those details make a broad claim of “natural” treatment insufficient for deciding suitability. The product label needs to be considered with the person’s history by the treating professional; this review supplies neither a dosing schedule nor a recommendation to start or change treatment.
The follow-up planning guide can help distinguish the intended benefit from concerns that need a response. Duke provides a place for that clinical discussion. The unresolved step is a clearly identified, individually assessed plan, including who will address medicine questions after the visit and which exact product information applies.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Duke Health — Menopause TreatmentOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- Duke Women’s Health Associates at Patterson PlaceOfficial health-system clinical service or location information; individual access, oral product and full price unconfirmed. · Checked 2026-09-29
- DailyMed — Prometrium progesterone capsule, Acertis Pharmaceuticals LLCCurrent exact oral Prometrium DailyMed label, updated July 23, 2026; patient leaflet revision February 2026. Does not establish provider supply. · Checked 2026-09-29
- FDA — Understanding the Risks of Compounded DrugsFederal primary drug-label or regulatory information; applies only within the stated product and regulatory scope. · Checked 2026-09-29